Disease · MONDO_0005005

clear cell renal carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. clear cell renal carcinoma. Diseases, record MONDO_0005005. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005005

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: clear cell renal carcinoma; Open Targets
Open Targets ID: MONDO_0005005; Open Targets
Other names: Grawitz tumor, Grawitz tumour, RCC, clear cell adenocarcinoma, clear cell adenocarcinoma of kidney, clear cell adenocarcinoma of the kidney, clear cell adenocarcinoma, kidney, clear cell carcinoma of kidney, clear cell carcinoma of the kidney, clear cell kidney carcinoma, clear cell renal cell cancer, clear cell renal cell carcinoma, conventional (clear cell) renal cell adenocarcinoma, conventional (clear cell) renal cell carcinoma, conventional renal cell carcinoma, hypernephroma, kidney clear cell adenocarcinoma, kidney clear cell carcinoma, renal cell carcinoma, clear cell adenocarcinoma, renal clear cell adenocarcinoma, renal clear cell carcinoma; Open Targets
Disease Ontology: DOID:4467; Disease Ontology
NCI Thesaurus: C4033; NCI Thesaurus
Orphanet: ORPHA:319276; Orphanet
Highest stage of its drugs: Phase 3, for 17 of its 106 drugs, from ClinicalTrials.gov; Open Targets

Drugs106

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
NIVOLUMAB	CHEMBL2108738	Antibody	Phase 3	ClinicalTrials.gov	31	31	31	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 3	ClinicalTrials.gov	19	19	19	Drugs and targets
BELZUTIFAN	CHEMBL4585668	Small molecule	Phase 3	ClinicalTrials.gov	14	14	14	Drugs and targets
CABOZANTINIB	CHEMBL2105717	Small molecule	Phase 3	ClinicalTrials.gov	14	14	14	Drugs and targets
LENVATINIB	CHEMBL1289601	Small molecule	Phase 3	ClinicalTrials.gov	13	13	13	Drugs and targets
EVEROLIMUS	CHEMBL1908360	Small molecule	Phase 3	ClinicalTrials.gov	10	10	10	Drugs and targets
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN	CHEMBL4594406	Protein	Phase 3	ClinicalTrials.gov	5	5	0	Drugs and targets
CASDATIFAN	CHEMBL6068220	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
GIRENTUXIMAB	CHEMBL1743027	Antibody	Phase 3	ClinicalTrials.gov	4	4	3	Drugs and targets
LUTETIUM LU 177 ZADAVOTIDE GURAXETAN	CHEMBL5314936	Small molecule	Phase 3	ClinicalTrials.gov	4	4	0	Drugs and targets

1 to 10 of 106

See all 106 drugs

Targets147

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KDR	Vascular endothelial growth factor receptor	13	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3791	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	12	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2324	Drugs and targets
PDCD1	Programmed cell death protein 1	12	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 3	https://conductscience.org/library/genes/5133	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	11	Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2321	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	10	Stem cell growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3815	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	10	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/5159	Drugs and targets
FLT3	Receptor-type tyrosine-protein kinase FLT3	5	Tyrosine-protein kinase receptor FLT3 inhibitor	Phase 2	https://conductscience.org/library/genes/2322	Drugs and targets
RET	Proto-oncogene tyrosine-protein kinase receptor Ret	5	Tyrosine-protein kinase receptor RET inhibitor	Phase 2	https://conductscience.org/library/genes/5979	Drugs and targets
CD274	Programmed cell death 1 ligand 1	4	Programmed cell death 1 ligand 1 binding agent; Programmed cell death 1 ligand 1 inhibitor; Programmed cell death 1 ligand 1 other	Phase 2	https://conductscience.org/library/genes/29126	Drugs and targets
CSF1R	Macrophage colony-stimulating factor 1 receptor	4	Macrophage colony stimulating factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/1436	Drugs and targets

1 to 10 of 147

See all 147 targets

Trials160

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 9 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00087022	Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer	Phase 3	864	2018-09-12	Kidney Cancer	GIRENTUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT01668784	Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)	Phase 3	821	2016-04-29	Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma	EVEROLIMUS, NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT03729245	A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)	Phase 3	623	2023-04-11	Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma	BEMPEGALDESLEUKIN, NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT00719264	Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer	Phase 2	365	2014-05-07	Carcinoma, Adenocarcinoma, Renal Cell, Nephroid Carcinoma, Hypernephroid	BEVACIZUMAB, EVEROLIMUS, INTERFERON ALFA-2A	Its record names the disease	ClinicalTrials.gov
NCT03117309	Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma	Phase 2	164	2025-07-10	Advanced Renal Cell Carcinoma	IPILIMUMAB, NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT01034631	BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma	Phase 1/2	154	2017-05-24	Renal Cell Carcinoma	BNC-105P, EVEROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT04489771	A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)	Phase 2	154	2024-02-28	Carcinoma, Renal Cell	BELZUTIFAN	Its record names the disease	ClinicalTrials.gov
NCT00455975	High-dose Bevacizumab in Advanced Renal Carcinoma Patients	Phase 2	119	2014-12-22	Renal Cancer, Kidney Cancer	BEVACIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT01358721	Phase I Biomarker Study (BMS-936558)	Phase 1	119	2019-07-26	Renal Cell Carcinoma	NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT02118337	A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies	Phase 1/2	97	2021-06-01	Select Advanced Malignancies, Kidney Cancer, Clear Cell Renal Cell Carcinoma	DURVALUMAB, NIVOLUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 160

See all 160 trials

Comparisons in its trials26

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Intervention vs Placebo: Disease-free Survival	192 of 433	197 of 431	864	NCT00087022	Trial comparisons
Intervention vs Placebo: Overall Survival	91 of 433	90 of 431	864	NCT00087022	Trial comparisons
Intervention vs Placebo: serious adverse events	36 of 431	36 of 424	855	NCT00087022	Trial comparisons
NIVOLUMAB vs EVEROLIMUS: deaths from any cause	324 of 406	342 of 397	803	NCT01668784	Trial comparisons
NIVOLUMAB vs EVEROLIMUS: serious adverse events	248 of 406	243 of 397	803	NCT01668784	Trial comparisons
Combination of Bempegaldesleukin + Nivolumab vs Sunitinib or Cabozantinib: deaths from any cause	109 of 310	114 of 306	616	NCT03729245	Trial comparisons
Combination of Bempegaldesleukin + Nivolumab vs Sunitinib or Cabozantinib: serious adverse events	113 of 310	91 of 306	616	NCT03729245	Trial comparisons
Bevacizumab, RAD001 (Everolimus) vs Bevacizumab, Interferon Alfa-2a (IFN): serious adverse events	79 of 180	76 of 181	361	NCT00719264	Trial comparisons
Cohort A: Nivolumab and Salvage Nivolumab/Ipilimumab in Clear Cell RCC vs Cohort B: Nivolumab and Salvage Nivolumab/Ipilimumab in Non-clear Cell RCC: Number of Participants With Adverse Events	128 of 128	35 of 35	163	NCT03117309	Trial comparisons
Belzutifan 200 mg vs Belzutifan 120 mg: deaths from any cause	28 of 78	25 of 76	154	NCT04489771	Trial comparisons

1 to 10 of 26

See all 26 comparisons in its trials

Papers from its trials81

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42927856	RESULT	1	PubMed
41115468	RESULT	1	PubMed
39233312	RESULT	1	PubMed
37011650	RESULT	1	PubMed
25788492	RESULT	1	PubMed
23665131	RESULT	1	PubMed
19010868	RESULT	1	PubMed
18272024	RESULT	1	PubMed
42719952	DERIVED	1	PubMed
42447427	DERIVED	1	PubMed

1 to 10 of 81

See all 81 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005005

GET https://conductscience.org/api/diseases/v1/MONDO_0005005/drugs?page=2

API reference For AI assistants